Pharsight

Addyi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7420057 SPROUT PHARMS Stable polymorph of flibanserin
Aug, 2022

(1 year, 7 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468639 SPROUT PHARMS Treating sexual desire disorders with flibanserin
Oct, 2022

(1 year, 5 months ago)

US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin
May, 2023

(10 months ago)

US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin
May, 2028

(4 years from now)

Addyi is owned by Sprout Pharms.

Addyi contains Flibanserin.

Addyi has a total of 4 drug patents out of which 3 drug patents have expired.

Expired drug patents of Addyi are:

  • US9468639
  • US8227471
  • US7420057

Addyi was authorised for market use on 18 August, 2015.

Addyi is available in tablet;oral dosage forms.

Addyi can be used as use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd).

The generics of Addyi are possible to be released after 09 May, 2028.

Drugs and Companies using FLIBANSERIN ingredient

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage

ADDYI family patents

Family Patents